Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention [12]

Medical Journal of Australia

Volumn 183, Issue 10, 2005, Pages 549-550

  Gibbs, Simon D J ^a   O'Grady, John ^a   Seymour, John F ^a   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE NECROSIS; BREAST CANCER; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HUMAN; JAW DISEASE; LETTER; MAXILLA; MULTIPLE MYELOMA; PROSTATE CANCER; TOOTH EXTRACTION; TOOTH INFECTION; TOOTH PAIN;

EID: 28444450407     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb07172.x     Document Type: Letter

References (4)

1. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182: 413-415.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
3. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005; 353: 99-102.
4. McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035-1043.